SAILIFEPharmaceuticals
Sai Life Sciences Ltd — Profit & Loss Statement
₹972.00
-1.32%
Sai Life Sciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -2.88 Cr | 3.78 Cr |
| Tax Rate For Calcs | 0.25 | 0.24 | 0.39 | 0.36 |
| Normalized EBITDA | 442.44 Cr | 314.58 Cr | 200.26 Cr | 138.86 Cr |
| Net Income From Continuing Operation Net Minority Interest | 170.13 Cr | 82.81 Cr | 9.99 Cr | 6.23 Cr |
| Reconciled Depreciation | 138.57 Cr | 119.44 Cr | 99.43 Cr | 90.16 Cr |
| Reconciled Cost Of Revenue | 465.76 Cr | 445.73 Cr | 461.48 Cr | 293.19 Cr |
| EBITDA | 442.44 Cr | 314.58 Cr | 192.90 Cr | 149.43 Cr |
| EBIT | 303.87 Cr | 195.14 Cr | 93.47 Cr | 59.27 Cr |
| Net Interest Income | -76.16 Cr | -85.91 Cr | -70.36 Cr | -46.13 Cr |
| Interest Expense | 76.16 Cr | 85.91 Cr | 77.06 Cr | 49.57 Cr |
| Normalized Income | 170.13 Cr | 82.81 Cr | 14.47 Cr | -0.56 Cr |
| Net Income From Continuing And Discontinued Operation | 170.13 Cr | 82.81 Cr | 9.99 Cr | 6.23 Cr |
| Total Expenses | 1.43K Cr | 1.30K Cr | 1.12K Cr | 833.66 Cr |
| Diluted Average Shares | 19.76 Cr | 20.80 Cr | 20.80 Cr | 20.80 Cr |
| Basic Average Shares | 19.27 Cr | 20.80 Cr | 20.80 Cr | 20.80 Cr |
| Diluted EPS | 8.61 | 3.98 | 0.48 | 0.30 |
| Basic EPS | 8.83 | 3.98 | 0.48 | 0.30 |
| Diluted NI Availto Com Stockholders | 170.13 Cr | 82.81 Cr | 9.99 Cr | 6.23 Cr |
| Net Income Common Stockholders | 170.13 Cr | 82.81 Cr | 9.99 Cr | 6.23 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 170.13 Cr | 82.81 Cr | 9.99 Cr | 6.23 Cr |
| Net Income Including Noncontrolling Interests | 170.13 Cr | 82.81 Cr | 9.99 Cr | 6.23 Cr |
| Net Income Continuous Operations | 170.13 Cr | 82.81 Cr | 9.99 Cr | 6.23 Cr |
| Tax Provision | 57.57 Cr | 26.43 Cr | 6.42 Cr | 3.47 Cr |
| Pretax Income | 227.70 Cr | 109.23 Cr | 16.41 Cr | 9.70 Cr |
| Other Non Operating Income Expenses | 36.78 Cr | 29.09 Cr | — | — |
| Net Non Operating Interest Income Expense | -76.16 Cr | -85.91 Cr | -70.36 Cr | -46.13 Cr |
| Interest Expense Non Operating | 76.16 Cr | 85.91 Cr | 77.06 Cr | 49.57 Cr |
| Operating Income | 267.09 Cr | 166.05 Cr | 76.83 Cr | 35.47 Cr |
| Operating Expense | 961.72 Cr | 853.39 Cr | 658.64 Cr | 540.47 Cr |
| Other Operating Expenses | 274.03 Cr | 239.05 Cr | 125.83 Cr | 106.49 Cr |
| Depreciation And Amortization In Income Statement | 138.57 Cr | 119.44 Cr | 99.43 Cr | 90.16 Cr |
| Depreciation Income Statement | 138.57 Cr | 119.44 Cr | 94.86 Cr | 86.92 Cr |
| Gross Profit | 1.23K Cr | 1.02K Cr | 735.47 Cr | 575.94 Cr |
| Cost Of Revenue | 465.76 Cr | 445.73 Cr | 461.48 Cr | 293.19 Cr |
| Total Revenue | 1.69K Cr | 1.47K Cr | 1.20K Cr | 869.12 Cr |
| Operating Revenue | 1.69K Cr | 1.47K Cr | 1.20K Cr | 869.12 Cr |
| Total Unusual Items | — | -13.45 Cr | -7.36 Cr | 10.57 Cr |
| Total Unusual Items Excluding Goodwill | — | -13.45 Cr | -7.36 Cr | 10.57 Cr |
| Interest Income | — | 13.60 Cr | 10.66 Cr | 7.05 Cr |
| Rent Expense Supplemental | — | 2.07 Cr | 5.13 Cr | 1.36 Cr |
| Special Income Charges | — | -13.45 Cr | -7.36 Cr | 10.57 Cr |
| Other Special Charges | — | -0.01 Cr | 0.57 Cr | -11.31 Cr |
| Write Off | — | 7.28 Cr | 6.80 Cr | 0.74 Cr |
| Impairment Of Capital Assets | — | 6.19 Cr | 0.00 | 0.00 |
| Total Other Finance Cost | — | 1.65 Cr | 3.97 Cr | 3.61 Cr |
| Interest Income Non Operating | — | 13.60 Cr | 10.66 Cr | 7.05 Cr |
| Amortization | — | 8.77 Cr | 4.57 Cr | 3.24 Cr |
| Selling General And Administration | — | 47.45 Cr | 31.15 Cr | 33.97 Cr |
| Selling And Marketing Expense | — | 8.16 Cr | 8.56 Cr | 7.74 Cr |
| General And Administrative Expense | — | 39.30 Cr | 22.59 Cr | 26.23 Cr |
| Rent And Landing Fees | — | 2.07 Cr | 5.13 Cr | 1.36 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sai Life Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.